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ABSTRACT
Glioblastoma are among the most angiogenic tumors. The molecular mechanisms 
that control blood vessel formation by endothelial cells (EC) in glioblastoma remain 
incompletely understood. Transforming growth factor-β (TGF-β) is a key regulatory 
cytokine that has proinvasive and stemness-maintaining autocrine properties in 
glioblastoma and confers immunosuppression to the tumor microenvironment. Here 
we characterize potential pro- and anti-angiogenic activities of TGF-β in the context 
of glioblastoma in vitro, using human brain-derived microvascular endothelial cells 
(hCMEC/D3) and glioblastoma-derived endothelial cells (GMEC) as model systems. 
We find that TGF-β induces vascular endothelial growth factor (VEGF) and placental 
growth factor (PlGF) mRNA expression and protein release in a TGF-β receptor (TβR) 
II / activin-like kinase (ALK)-5-dependent manner under normoxia and hypoxia, 
defining potential indirect proangiogenic activity of TGF-β in glioblastoma. In parallel, 
exogenous TGF-β has also inhibitory effects on EC properties and induces endothelial-
mesenchymal transition (EndMT) in hCMEC and GMEC. Accordingly, direct inhibition of 
endogenous TGF-β/ALK-5 signalling increases EC properties such as tube formation, 
von-Willebrand factor (vWF) and claudin (CLDN) 5 expression. Yet, the supernatant of 
TGF-β-stimulated hCMEC and GMEC strongly promotes EC-related gene expression and 
tube formation in a cediranib-sensitive manner. These observations shed light on the 
complex pro- and anti-angiogenic pathways involving the cross-talk between TGF-β 
and VEGF/PLGF signalling in glioblastoma which may involve parallel stimulation of 
angiogenesis and EndMT in distinct target cell populations.
INTRODUCTION
Blood supply is an essential prerequisite for 
solid tumor growth and therefore a bona fide target for 
intervention. The processes by which tumors initiate 
and maintain their blood supply are complex and have 
remained incompletely understood. Vasculogenesis 
is defined as the initial migration and differentiation 
of endothelial precursor cells to form blood vessels 
de novo. Subsequent to this, angiogenesis occurs by the 
formation of new blood vessels from pre-existing ones, 
also termed sprouting angiogenesis. Angiogenesis in 
glioblastoma is characterized by a neovasculature that has 
an erratic basement membrane, reduced pericyte coverage, 
decreased astrocytic end feet association with blood 
vessels, and altered expression of adhesion molecules on 
endothelial cells (EC) [1]. This abnormal vascularization 
causes excessive leakiness and promotes edema formation.
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One traditional view states that hypoxic tumor cells 
release vascular endothelial growth factor (VEGF) which 
in turn counteracts tumor hypoxia by mediating the growth 
of new blood vessels. However, it is unlikely that all blood 
vessel formation in glioblastoma is triggered by hypoxia-
mediated VEGF signaling, notably early in the disease 
course when there is probably little hypoxia. Thus, alternative 
pathways regulating tumor-associated angiogenesis beyond 
hypoxia-driven VEGF synthesis are likely to exist.
Transforming growth factor (TGF)-β is a prototype 
member of a cytokine family involved in most cancer-
associated processes. In glioblastoma, immunosuppression 
and autocrine control of migration, invasiveness and 
stemness have received most attention. However, TGF-β 
has also been implicated in angiogenesis in various 
model systems including physiological and pathological 
angiogenesis. Direct TGF-β signalling on endothelial 
cells has been linked mainly to two type I receptors, 
activin-like receptor kinases (ALK)-1 and ALK-5. These 
two TGFβR I-mediated pathways have been attributed 
to opposing effects in response to TGF-β: ALK-1 on 
interaction with TβRII induced Smad 1/5 phosphorylation 
to induce endothelial cell proliferation [2] and migration 
[3] whereas ALK-5 recruited by TβRII induces Smad 2/3 
phosphorylation, thereby inhibiting the above-mentioned 
effects [3]. TGF-β family ligands can interact with co-
receptors represented by endoglin (CD105), which is 
highly expressed in proliferating endothelial cells, and 
betaglycan (TβRIII). In the present study, we investigated 
the interaction and dependence of these key signaling 
pathways and their role for glioma angiogenesis, using 
hCMEC and GMEC as models.
RESULTS
hCMEC express TGF-β receptors and 
coreceptors
We first analysed whether TGF-β receptors (TβRII, 
ALK-1 and ALK-5) and co-receptors (endoglin and 
TβRIII) were expressed at mRNA and protein level 
in hCMEC. All receptors were expressed at mRNA 
level under normoxia and hypoxia, without significant 
differences (p > 0.05) (Figure 1A). TβRII, endoglin and 
TβRIII protein levels were also unaltered in hypoxia 
(Figure 1B–1D). Hypoxia decreased pSmad1/5 and Smad5 
levels, but did not affect pSmad2, Smad2, Smad1 or 
secreted levels of TGF-β. Like most non-neoplastic cells, 
hCMEC released more unprocessed than active TGF-β 
(Supplementary Figure 1A).
After confirming the expression of the TGF-β 
receptors and ligand, we transiently silenced TβRII, ALK-
1, ALK-5, endoglin or TβRIII in the absence or presence of 
TGF-β. Silencing was confirmed at the mRNA and protein 
levels wherever feasible (Figure 1E–1F). The specificity of 
silencing ALK-1 versus ALK-5 was verified by RT-PCR 
(Supplementary Figure 1B–1C). Interestingly, exposure to 
exogenous TGF-β decreased TβRIII and increased ALK-5 
at mRNA level and endoglin expression at mRNA and 
protein levels. Constitutive pSmad2 was faintly detectable 
and not induced by receptor silencing. Constitutive pSmad1/5 
levels increased mildly with silencing of endoglin, but not 
with silencing of the other receptors (Figure 1E–1F). TGF-β 
strongly induced pSmad2, and this induction was attenuated 
by the silencing of TβRII, ALK-1, ALK-5 or endoglin, 
although not TβRIII. TGF-β strongly decreased pSmad1/5 
levels, and this effect was attenuated somewhat by the 
silencing of ALK-1, ALK-5, TβRII, TβRIII or endoglin, but 
robustly by SD-208. TβRII levels were strongly reduced at 72 
h after exposure to TGF-β (Figure 1F).
Under these experimental conditions, exposure 
of hCMEC to TGF-β did not induce significant loss 
of viability assessed by trypan blue dye exclusion, 
cell cycle arrest assessed by PI staining or features of 
apoptosis as assessed by annexin V / propidium labeling 
(Supplementary Figure 2).
TGF-β induces VEGF mRNA expression and 
protein release in hCMEC under normoxic 
and hypoxic conditions
We next investigated the effect of recombinant 
TGF-β on VEGF expression in hCMEC at increasing 
concentrations for 24 h either at normoxia or under 
hypoxic conditions (1% O2). VEGF mRNA expression 
and protein release were increased approximately 10-
fold when the cells were shifted to hypoxia. Exposure to 
TGF-β increased VEGF mRNA expression and protein 
release in a concentration- and time-dependent manner, 
more significantly even in hypoxia than under normoxic 
conditions (Figure 2A–2D). The lowest concentration 
of TGF-β (0.1 ng/ml) did not increase VEGF protein 
in normoxia whereas the increase was significant in 
hypoxia. The induction of VEGF mRNA expression was 
not restricted to a specific VEGF isoform (Figure 2E). 
Hypoxia increased PlGF mRNA expression, moreover, 
the combination of hypoxia and TGF-β resulted in a 
further enhancement compared to hypoxia or TGF-β 
alone (Figure 2F). PlGF release was increased by TGF-β 
or hypoxia, and the combination was more effective than 
either treatment alone (Figure 2G).
TGF-β-mediated induction of VEGF mRNA 
and release in hCMEC involves TβRII, ALK-5 
and TβRIII
To determine the relative contribution of TGF-β 
receptors and co-receptors to the TGF-β-mediated increase 
of VEGF and PlGF in hCMEC, we examined their 
modulation by gene silencing of TβRII, ALK-1, ALK-5, 
endoglin or TβRIII. TβRII, ALK-1, ALK-5 and endoglin 
gene silencing had no effect on constitutive VEGF release 
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Figure 1: hCMEC express TGF-β receptors and coreceptors. A–D. The levels of mRNA for TGF-β receptors RII, ALK-1, ALK-
5 and endoglin or RIII were assessed by RT-PCR (A) and protein by immunoblot (B) or flow cytometry (C, D) as feasible under normoxia 
and hypoxia. Data in A are expressed as mean values and SD (n = 4). E, F. TGF-β receptor gene silencing was verified on mRNA (n = 3) and 
protein level. In F, the effect of TGF-β receptor gene silencing on constitutive and TGF-β (10 ng/ml, 72 h)-evoked pSmad2 and pSmad1/5 
levels was studied by immunoblot. SD-208 (1 μM, 72 h) was included to confirm the ALK-5 findings (n = 3). (*p < 0.05, **p < 0.01, ***p 
< 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of specific siRNA, +++p < 0.001, effect of TGF-β).
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Figure 2: TGF-β induces VEGF and PlGF release by endothelial cells. A, B. hCMEC were seeded in full medium, serum-
starved for 24 h, and then cultured in the absence or presence of TGF-β at the indicated concentrations in normoxia or hypoxia and assessed 
for VEGF mRNA expression by qRT-PCR at 12 h (A) or VEGF protein concentrations in the supernatant by ELISA at 24 h (B) C, D. 
Similar experiments as in A, B were performed to assess the time dependency of VEGF modulation by TGF-β. E, F. The expression of 
VEGF isoforms (E) or PlGF (F) mRNA was investigated by qRT-PCR (VEGFXXXA, proangiogenic isoforms, VEGFXXXB, weakly 
angiogenic isoforms). G. PlGF concentrations in the supernatant were analyzed by ELISA. Data are expressed as mean and SD (n = 3) 
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA followed by Tukey’s post hoc test, hypoxia versus normoxia, 
+p < 0.05, ++p < 0.01, +++p < 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of TGF-β).
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whereas silencing of TβRIII reduced VEGF release by 
2-fold. In contrast, when VEGF release was induced by 
exogenous TGF-β, silencing of TβRII, ALK-5 or TβRIII 
was inhibitory (Figure 3A). Silencing of TGF-β receptors 
did not modulate constitutive PlGF release, however 
TβRII or ALK-5 depletion significantly inhibited TGF-β-
induced PlGF secretion (Figure 3B).
The important signaling function of ALK-5 was 
confirmed by pharmacological studies using SD-208 
which demonstrated no effect on constitutive VEGF 
release, but strong activity against TGF-β-evoked VEGF 
gene transcription and protein release (Figure 3C–3D). 
This effect was not restricted to specific VEGF mRNA 
isoforms (Supplementary Figure 3). Under hypoxic 
conditions, SD-208 even inhibited constitutive VEGF 
release. The effects of TGF-β and accordingly SD-208 
were overall more prominent for PlGF than for VEGF 
(Figure 3E–3F).
Transcriptional regulation of TGF-β-evoked 
VEGF release
To elucidate the transcriptional regulation of VEGF 
by TGF-β, 2 major transcription factors known to have 
multiple response elements on the promoter region 
of VEGF, namely, specificity protein (SP1) and early 
growth response (EGR)1 were screened for basal mRNA 
expression in hCMEC, HUVEC and two glioma cell lines, 
U87MG and LN-18 (Supplementary Figure 4A–4B). All 
cells expressed SP1 and EGR1. SP1 and EGR1 mRNA 
expression decreased with TGF-β exposure at 1–6 h 
in hCMEC, however, protein levels were unaffected 
(Supplementary Figure 4C). Moreover, the silencing of 
SP1 did not alter VEGF mRNA expression or protein 
release (Supplementary Figure 4D). Hence, these data 
do not support the idea that these transcription factors 
are involved in the TGF-β-evoked increase of VEGF in 
hCMEC in normoxia.
TGF-β induces endothelial mesenchymal 
transition (EndMT) and TGF-β-stimulated 
supernatant increases tube formation via 
VEGFR signaling in hCMEC
We noted that exposure to TGF-β caused changes 
in the morphology of hCMEC, making the cells more 
elongated and spindle-like in a SD-208-sensitive, thus 
presumably ALK-5-dependent manner (Figure 4A). 
Interestingly, however, SD-208 alone induced tube 
formation, endothelial cell sprouting and expression of 
the tight junction marker, CLDN5. Conversely, exogenous 
TGF-β blocked the formation of tubes and sprouts 
and decreased vWF and CLDN5 mRNA expression. 
Pretreatment with SD-208 rescued tube formation, 
sprouting, vWF and CLDN5 mRNA expression (Figure 
4B–4D). Further, TGF-β increased integrin β3 and β5, 
snail family zinc finger (SNAI) 1 and N-cadherin mRNA 
expression and protein levels and pretreatment with SD-
208 attenuated this increase (Figure 4D–4F). Altogether, 
the pattern of decreased vWF [4], CLDN5 [5, 6] with a 
concomitant increase in β3 [7] and β5 integrin expression 
[8], SNAI1 [5, 9] and N-cadherin [10] are prominent 
signs of mesenchymal transition. To dissect the apparent 
opposing pro- and anti-angiogenic effects of TGF-β on 
hCMEC, we changed the experimental paradigm and 
isolated the effect of TGF-β-induced VEGF on tube 
formation and cell sprouting by using supernatants of 
hCMEC treated with TGF-β for 96 h. These were added 
to hCMEC that had been pre-treated with vehicle (DMSO) 
or SD-208. Under these conditions, TGF-β-stimulated 
supernatant increased tube formation and sprouting. SD-
208 super-induced these pro-angiogenic effects of TGF-
β-stimulated supernatants, consistent with antagonistic 
activity of endogenous or supernatant-derived TGF-β and 
illustrating how TGF-β and VEGF counterbalance the 
endothelial phenotype. Cediranib, a pan-VEGFR inhibitor, 
decreased constitutive and TGF-β-stimulated supernatant-
induced tube formation in the absence or presence of SD-
208 (Figure 4G).
Endothelial properties of glioblastoma-derived 
endothelial cells (GMEC)
Finally we wished to confirm the principle 
observations summarized above in freshly isolated CD31-
positive ex vivo endothelial cells (ZHE-459, ZHE-464, 
ZHE-483–2) from glioblastoma tissue. Their endothelial 
nature was verified by CD31, CD34, and vWF expression 
and by their tube formation capacity (Supplementary 
Figure 5A–5B). CD31 mRNA expression in the CD31-
positive ZHE-464 cells at P5 was reduced approximately 
50 times compared to that on the day of isolation whereas 
CD31-negative cells did not express CD31 even after 5 
passages in endothelial medium, DMEM or neurobasal 
medium (Supplementary Figure 5C).
Reduction of VEGF receptor levels in hypoxia in 
hCMEC and GMEC
The basal expression of VEGFR-1 and VEGFR-2 
was determined at mRNA and protein levels at normoxia 
or after 24 h of hypoxia in hCMEC and GMEC. VEGFR-1 
and VEGFR-2 mRNA expression did not change in 
hypoxia in hCMEC (Figure 5A). VEGFR-1 protein 
levels at the cell surface and after permeabilization were 
not altered (Figure 5B). In contrast, there was a strong 
decrease in VEGFR-2 protein levels under hypoxia as 
assessed by immunoblot (Figure 5C). In ZHE-464 the 
mRNA expression of VEGFR-1 increased, whereas 
VEGFR-2 was reduced at the mRNA and protein levels in 
hypoxia (Figure 5D), suggesting differential regulation of 
the VEGF receptors by hypoxia.
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Figure 3: TGF-β-mediated induction of VEGF in endothelial cells involves RII, ALK-5 and RIII. A. The effect of TGF-β 
receptor gene silencing on constitutive or TGF-β-evoked VEGF release was assessed by ELISA at 72 h (*p < 0.05, **p < 0.01, ***p < 
0.001, one way ANOVA followed by Tukey’s post hoc test, effect of specific siRNA, +p < 0.05, ++p < 0.01, +++p < 0.001, effect of TGF-β). 
B. The effect of TGF-β receptor gene silencing on constitutive or TGF-β-evoked PlGF release was assessed by ELISA at 72 h (*p < 0.05, 
**p < 0.01, ***p < 0.001, effect of specific siRNA, ++p < 0.01, +++p < 0.001, effect of TGF-β). C–F. The modulation of constitutive or TGF-
β-evoked VEGF (C, D) or PlGF (E, F) mRNA expression (C, E) or protein release (D, F) by hypoxia or SD-208 or both was determined 
by RT-PCR or ELISA. Data are expressed as mean and SD (n = 3). (*p < 0.05, *p < 0.01, ***p < 0.001, two-way ANOVA, hypoxia versus 
normoxia, +p < 0.05, ++p < 0.01, +++p < 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of TGF-β, ΦΦΦ p < 0.001, one-
way ANOVA followed by Tukey’s post hoc test, effect of SD-208).
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Figure 4: TGF-β induces EndMT in hCMEC and TGF-β-stimulated hCMEC supernatant increases tube formation. A. 
hCMEC were seeded in full medium, treated with TGF-β (10 ng/ml) or SD-208 (1 μM) for 96 h, and examined by phase contrast microscopy. 
B. Tube formation was quantified by assessing the number of tubes (n), tube length (mm) and number of branching points (n). C. Endothelial 
cell sprouting was assessed by counting numbers of sprouts (n). D. mRNA expression of vWF, CLDN5, β3 and β5 integrins, SNAI1 and 
N-cadherin was assessed by qRT-PCR under the same conditions as in A, for 72 h. Data are expressed as mean and SD (n = 3) (+p < 0.05, 
++p < 0.01, +++p < 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of TGF-β, ΦΦ p < 0.01, ΦΦΦ p < 0.001, effect of SD-
208). E. Protein levels of SNAI1 and N-cadherin were assessed by immunoblot under the same conditions as A at 96 h. F. Protein levels 
of αvβ3 and αvβ5 was assessed by flow cytometry under the same conditions as in A, at 96 h. G. hCMEC supernatant treated with TGF-β 
for 96 h was concentrated and added with or without cediranib (1 μM) to hCMEC pretreated with DMSO or 1 μM SD-208 for 1 h. Tube 
formation was assessed after 12 h, by determining the number of tubes and tube length. Data are expressed as mean and SD (n = 3) (ΦΦ p 
< 0.01, ΦΦΦ p < 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of SD-208, +p < 0.05, ++p < 0.01, +++p < 0.001, effect of 
TGF-β-stimulated supernatant, #p < 0.05, ###p < 0.001, effect of cediranib).
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Figure 5: Modulation of VEGFR expression by hypoxia in hCMEC and GMEC. A. VEGFR-1 or VEGFR-2 mRNA 
expression were assessed under normoxia or 24 h of hypoxia by qRT-PCR. B. Basal levels of extracellular or intracellular VEGFR-1 
protein were assessed by flow cytometry under normoxia or hypoxia, SFI are indicated. C. VEGFR-2 levels of hCMEC were assessed by 
immunoblot. D. Similar experiments as in A and C were performed in ZHE-464. Data are expressed as mean and SD (n = 3). (*, effect of 
hypoxia, student t-test).
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TGF-β control of VEGF release in GMEC
Silencing of ALK-5 in the GMEC was confirmed by 
RT-PCR (Supplementary Figure 5D). Exogenous TGF-β 
induced pSmad2 and pSmad1/5 in GMEC, and ALK-
5 silencing attenuated this effect (Figure 6A). Further, 
silencing of ALK-5 reduced constitutive VEGF release 
in ZHE-459 and ZHE-483–2. TGF-β increased VEGF in 
an ALK-5-dependent fashion in ZHE-459, ZHE-464 and 
ZHE-483–2 (Figure 6B). Similarly, silencing of ALK-5 
reduced constitutive and TGF-β-evoked PlGF release in 
ZHE-459, ZHE-464 and ZHE-483–2 (Figure 6B).
TGF-β induces EndMT and TGF-β-stimulated 
supernatant increases tube formation via 
VEGFR signaling in GMEC
Tube formation was enhanced by pharmacological 
inhibition of ALK-5 in ZHE-459, ZHE-464 and ZHE-
483–2. Conversely, TGF-β inhibited tube formation, 
but pre-treatment with SD-208 rescued tube formation, 
confirming that TGF-β inhibits angiogenic properties via 
ALK-5 in GMEC, too (Figure 6C). Further, TGF-β induced 
EndMT in ZHE-464 and ZHE-483–2. TGF-β reduced the 
apico-basal polarity of ZHE-464 and created more spindle 
shaped ZHE-483–2 cells. TGF-β decreased vWF and 
CLDN5 in ZHE-464 and ZHE-483–2, and concomitantly 
increased SNAI1 and N-cadherin in an ALK-5-dependent 
manner, very similar to hCMEC (Figure 7A–7B). Similar 
to hCMEC, cediranib suppressed the constitutive and TGF-
β-stimulated supernatant-induced tube formation in the 
absence or presence of SD-208 in ZHE-459 (Figure 7C).
DISCUSSION
Angiogenesis is an important step in the multi-step 
formation of solid cancers including glioblastoma. It 
requires a crosstalk between tumor and endothelial cells 
that is likely to involve much more complex interactions 
than merely hypoxic tumor cell-derived VEGF acting 
on endothelial cells. Targeting blood vessel formation in 
glioblastoma has been the favored therapeutic strategy 
in clinical drug development in the first decade of this 
century. Yet, the failure of multiple drugs acting not only 
on VEGF or its receptors, but also on alternative targets 
including integrins has imposed a brake on further efforts 
of targeting angiogenesis and instead called for a better 
understanding of the processes that govern glioblastoma-
associated blood vessel formation [11].
Primary resistance to or escape from anti-angiogenic 
therapy in glioblastoma is likely to be mediated by 
compensatory activation of multiple pro-angiogenic 
pathways and shaped by complex interactions between 
tumor cells and their microenvironment [12]. VEGF 
remains to be the major molecule thought to drive 
endothelial cell growth, migration, vessel dilation and 
permeability. VEGF, VEGF-B, VEGF-C, VEGF-D and 
PlGF represent a family of related growth factor molecules 
which bind to VEGFR1–3 with varying affinity. VEGF 
binding to VEGFR-2 is critically required for vascular 
development and sprouting, maturation and differentiation 
of endothelial cells [13].
TGF-β is a multifunctional cytokine that has 
been strongly associated with the malignant phenotype 
of glioblastoma and become an attractive target for 
pharmacological intervention [14, 15] Here we report 
that hCMEC express all known TGF-β receptors and 
coreceptors (Figure 1). Their constitutive VEGF release 
was largely unaffected by TGF-β receptor gene silencing 
except for the effect of TβRIII coreceptor silencing 
(Figure 3A), suggesting that TβRIII exerts activity beyond 
TGF-β signaling in this paradigm [16]. Exogenous TGF-β 
induced VEGF mRNA synthesis and protein release in 
hCMEC in a time- and concentration-dependent manner 
(Figure 2). The inhibition of VEGF release by ALK-5 
gene silencing or pharmacological inhibition using SD-
208 led to the identification of ALK-5 as the principal 
type 1 receptor mediating the VEGF induction by TGF-β 
(Figure 3), consistent with the observation that ALK-5–/– 
mouse endothelial cells obtained from E9.5 embryos 
shows reduced VEGF mRNA expression [17].
TGF-β has been shown to increase PlGF mRNA 
and protein release in keratinocytes [18] and in retinal 
epithelium [19]. We show that TGF-β induces PlGF 
expression and release in endothelial cells in normoxic 
(Figure 2, Figure 3 and Figure 6) and hypoxic conditions 
(Figure 3). We further show that ALK5 mediates the 
effects of TGF-β on PlGF and that hypoxia may super-
induce the PlGF system in the context of glioblastoma.
We observed that VEGFR-2 protein levels in 
hCMEC and GMEC decreased under hypoxia (Figure 5). 
Up-regulation of VEGFR-1 and down-regulation of 
VEGFR-2 at the mRNA and protein levels have been 
reported previously in HUVEC exposed to hypoxia [20, 
21]. The promoter regions of VEGFR-1 that have HIF 
response elements (HRE) were identified whereas no 
obvious HRE on the VEGFR-2 promoter region was 
detected. It was speculated that the regulation of VEGFR-2 
in hypoxia was mediated by an unindentified paracrine 
soluble factor [20] or through post-transcriptional 
mechanisms [21]. In response to VEGF-A, hypoxic 
human dermal microvascular endothelial cells (HDMEC) 
displayed a reduction in VEGFR-2 phosphorylation 
compared with normoxia, indicating reduced VEGF-A-
induced receptor activation in hypoxia [22].
We find that TGF-β induces EndMT in hCMEC 
and GMEC as determined by a decrease in the expression 
of the endothelial markers vWF and CLDN5, inhibition 
of tube formation and an increase in the expression of 
the mesenchymal markers SNAI1 and N-cadherin in an 
ALK-5-dependent manner (Figure 4 and Figure 7). TGF-
β-induced mesenchymal transition of mouse pancreatic 
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Figure 6: TGF-β control of VEGF release in glioblastoma-derived endothelial cells (GMEC). A. The effect of ALK-5 gene 
silencing on constitutive and TGF-β (10 ng/ml, 72 h)-evoked pSmad2 and pSmad1/5 levels was studied by immunoblot. B. The effect of 
ALK-5 gene silencing on constitutive or TGF-β-evoked VEGF (left) or PlGF (right) release was assessed by ELISA at 72 h in ZHE-459, 
ZHE-464 and ZHE-483–2. Data are expressed as mean and SD (n = 3). (Φ p < 0.05, ΦΦ p < 0.01, ΦΦΦ p < 0.001, one way ANOVA 
followed by Tukey’s post hoc test, effect of si ALK-5, +p < 0.05, ++p < 0.01, +++p < 0.001, effect of TGF-β). C. ZHE-459, ZHE-464 or ZHE-
483–2 cells were seeded in full medium and treated with TGF-β (10 ng/ml) or SD-208 (1 μM) for 96 h. Tube formation was monitored and 
quantified using number of tubes, tube length and number of branching points as read-outs. Data are expressed as mean and SD (n = 3). (Φ 
p < 0.05, ΦΦ p < 0.01, ΦΦΦ p < 0.001, one way ANOVA followed by Tukey’s post hoc test, effect of SD-208, +p < 0.05, ++p < 0.01, +++p 
< 0.001, effect of TGF-β).
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Figure 7: TGF-β induces EndMT and TGF-β-stimulated supernatant increases tube formation in GMEC. A, B. ZHE-
464 (A) or ZHE-483–2 (B) were seeded in full medium and treated with TGF-β (10 ng/ml) or SD-208 (1 μM) for 96 h. Phase contrast 
images are shown. mRNA expression and protein levels of vWF, CLDN5, SNAI1 and N-cadherin were assessed by qRT-PCR at 72 h and 
immunoblot at 96 h respectively under the same conditions. Data are expressed as mean and SD (n = 3) (Φ p < 0.05, ΦΦ p < 0.01, ΦΦΦ 
p < 0.001, one way ANOVA followed by Tukey’s post hoc test, effect of SD-208, +p < 0.05, ++p < 0.01, +++p < 0.001, effect of TGF-β). C. 
ZHE-459 supernatant treated with TGF-β for 96 h was concentrated and added with or without cediranib (1 μM) to ZHE-459 pretreated 
with DMSO or 1 μM SD-208 for 1 h. Tube formation was assessed after 12 h, by calculating the number of tubes and tube length. Data are 
expressed as mean and SD (n = 3) (ΦΦ p < 0.01, ΦΦΦ p < 0.001, one-way ANOVA followed by Tukey’s post hoc test, effect of SD-208, +p 
< 0.05, ++p < 0.01, effect of TGF-β-stimulated supernatant, #p < 0.05, ##p < 0.01, ###p < 0.001, effect of cediranib).
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microvascular endothelial cells required Smad-dependent 
cooperative activation of Rho signals and MRTF-A [23]. 
TGF-β promoted SNAI1-mediated EndMT through 
convergence of Smad-dependent and Smad-independent 
signalling in human cutaneous microvascular endothelial 
cells [24]. Sustained elevation of SNAI1 has been 
suggested to promote a glial-mesenchymal transition in 
gliomas after radiation [25].
VEGF and TGF-β signalling may induce a plethora 
of gene expression changes observed in glioblastoma 
vessels in vivo [26]. The dual effects of TGF-β on 
biological aspects of angiogenesis characterized here 
(Figure 8) makes the consequences of therapeutic 
targeting of either pathway difficult to predict. It must 
be acknowledged that therapeutic targeting of VEGF 
receptors by cediranib has failed in glioblastoma [27] 
whereas bevacizumab, while convincingly delaying 
disease progression, also did not impact overall survival 
[28, 29]. Yet, it has remained uncertain to what extent 
these drugs truly reached their desired site of action 
which must include the tumor microenvironment. Blood 
brain barrier permeability may have limited the efficacy 
of cediranib and bevacizumab would a priori only 
be able to scavenge humoral VEGF, but probably not 
be able to prevent autocrine signaling that is likely to be 
relevant in glioblastoma, too [30]. Accordingly, control 
of VEGF synthesis and release is still a valid target in 
glioblastoma.
Figure 8: Two pathways of TGF-β/ALK-5 signalling in hCMEC and GMEC. TGF-β can increase VEGF/PlGF secretion via 
the ALK-5 pathway and create a pro-angiogenic milieu for the tumor or induce EndMT by decreasing endothelial properties and increasing 
the mesenchymal signatures for the tumor to become potentially more invasive.
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MATERIALS AND METHODS
Reagents
Recombinant human TGF-β2 was purchased from 
R&D Systems (Minneapolis, MN, USA). All experiments 
reported herein involving exogenous supplementation 
were performed with human TGF-β2. Selected experiments 
were confirmed using human TGF-β1 (data not shown). 
SD-208 [14], a TGF-βRI kinase inhibitor was provided 
by Scios (Fremont, CA, USA). Cediranib (AZD2171) was 
purchased from Biovision (Milpitas, CA, USA).
Cell culture
Human cerebral microvascular endothelial cells 
(hCMEC/D3), kindly provided by P.C. Couraud (Paris, 
France), human glioblastoma-derived endothelial cells 
ZHE-459, ZHE-464 and ZHE-483–2 and human umbilical 
vein endothelial cells (HUVEC) were cultured in Lonza 
EBM™-2 medium (CC-3156, Lonza, Walkersville, MD, 
USA) with supplements (EGM-2-CC4176) that include 
0.5 ml human recombinant epidermal growth factor 
(hEGF, CC-4317A), 0.2 ml hydrocortisone (CC-4112A), 2 
ml human fibroblast growth factor-B (hFGF, CC-4113A), 
0.5 ml VEGF (CC-4114A), 0.5 ml recombinant long-
insulin like growth factor (R3-IGF-1, CC-4115A), 0.5 ml 
ascorbic acid (CC-4116A), 0.5 ml heparin (CC-4396A), 
0.5 ml gentamicin sulphate amphotericin B (GA-1000, 
CC-4381A), 10 ml (2%) fetal bovine serum (FBS, CC-
4101A) and 5 ml (1 M) HEPES (Gibco, GrandIsland, 
NY, USA) and 5 ml CD lipid concentrate (Gibco). 
hCMEC/D3 were cultured from P30-P37 on Corning® 
BioCoat™ collagen type I cellware (Corning) and used 
for experiments. HUVEC, ZHE-459, ZHE-464 and ZHE-
483–2 cells were cultured from P2-P7 on the same dishes 
as hCMEC/D3. All cells were grown in a humidified 37°C 
incubator with 5% CO2. All starvation experiments for 
endothelial cells were performed with plain Lonza EBM™-
2 medium without any supplements. LN-308, a longterm 
adherent glioma cell line, was cultured in Dulbecco’s 
modified eagle’s medium (DMEM) containing 10% fetal 
calf serum (FCS) and 1% glutamine (Gibco). For all 
experiments LN-308 cells were starved for 24 h in DMEM 
containing 1% glutamine.
Isolation of human glioblastoma-derived 
endothelial cells
The net weight of the glioma tissue was measured 
followed by dissociation with 10 mg/ml collagenase/
dispase (11097113001, Roche, Basel, Switzerland) 
and rotation with gentleMACS C-tubes (130–093-237, 
Miltenyi biotech, Cologne, Germany). Erythrocytes were 
lysed by resuspending and incubating the cells in a 3:1 
ratio of water:PBS. Cells were then counted and 20 μl 
of FcR blocking reagent and 20 μl of CD31 microbeads 
(130–091-935, Miltenyi biotech) were added per 107 
cells. After 15 min rotating incubation at 4°C, the cells 
were passed through a 40 μm cell strainer to remove 
cell aggregates. Cells were then passed through an LS 
column placed in a magnetic field of a MACS separator. 
The cells that pass through (CD31-negative population) 
were again passed through another LS column to get a 
purer CD31-negative population. These cells were divided 
into 3 fractions and grown in Neurobasal medium (NBM) 
supplemented with B-27 (20 μl/ml) and Glutamax (10 μl/
ml) (Invitrogen, Carlsbad, CA, USA), FGF and EGF (20 
ng/ml each; Peprotech, Rocky Hill, PA, USA), DMEM 
supplemented with 10% FCS and 1% L-glutamine (Gibco) 
or endothelial medium (EM). The CD31-positive cells 
which remained in the column were forcefully washed 
out and cultured in collagen type I-coated dishes until 
confluency and passaged once more before use. For 
ZHE-483–2, CD45-positive cells were depleted using LD 
columns (130–042-901, Miltenyi biotech), and then from 
the CD45-negative population, CD31-positive cells were 
isolated using the above procedure.
Real-time (RT) PCR
Total RNA was prepared with the NucleoSpin 
System (Macherey-Nagel, Düren, Germany) and cDNA 
was transcribed using Superscript II reverse transcriptase 
(Bio-rad, Munich, Germany). For real-time PCR, 
cDNA amplification was monitored using SYBR Green 
chemistry on the 7300 Real time PCR System (Applied 
Biosystems, Zug, Switzerland). The conditions for these 
PCR reactions were: 40 cycles, 95°C/15 sec, 60°C/1 min, 
using the primers specified in Supplementary Table 1. 
Arf1 transcript levels were used as a reference for 
relative quantification of mRNA expression levels using 
the ΔCT method because they were observed to be stable 
within each cell line under the experimental conditions 
reported here.
Immunoblot
RIPA buffer (pH 7.8) consisting of 1% V/V NP-40, 
5% sodium deoxycholate (0.5% V/V) (Sigma Aldrich, 
Buchs, Switzerland), 1 M Tris/HCl pH 8.0 (Merck KGaA, 
Darmstadt, Germany), 5 M NaCl (Merck KGaA), 0.5 M 
EDTA, pH 8.0 (Sigma) and MilliQ H2O was prepared, 
sterile-filtered and stored at 4°C. Phosphatase inhibitor 
cocktail (Sigma), protease inhibitor cocktail sets III and 
IV (Sigma), 200 mM sodium orthovanadate (pH 10) 
and 0.5 M sodium fluoride were added freshly to the 
RIPA buffer before lysing the cells. After this, protein 
levels were determined using a Bradford-based protein 
assay (Biorad). Denatured whole protein lysates (40 μg/
lane) were separated on 10–15% acrylamide gels. After 
transfer to nitrocellulose (Biorad), blots were blocked 
in TBST containing 5% skim milk and incubated 
overnight at 4°C with primary antibodies. Rabbit anti-
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human TβRII (1:1000) ((C-16)-R, sc220-R, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), rabbit anti-CD105 
(1:3000) (ab137389, abcam, Cambridge, UK), goat anti-
TβRIII (1:2000) (AF-242-PB, R&D Systems), rabbit 
anti-VEGFR-2 (1:1000) (Cell Signaling, Danvers, MA), 
rabbit anti-pSmad2 (1:1000) (3108S, Cell Signaling), 
rabbit anti- Smad2 (1:1000) (3122S, Cell Signaling), 
rabbit anti-Smad1 (1:1000) (9743S, Cell Signaling), rabbit 
anti-Smad5 (1:1000) (9517S, Cell Signaling), rabbit anti-
pSmad1/5 (1:1000) (9516S, Cell Signaling), rabbit anti-
vWF (1:1000) (sc-14014, Santa Cruz Biotechnology), 
rabbit anti-CLDN5 (1:1000) (ABT45, Millipore, Billerica, 
MA, USA), rabbit anti-Snail (1:1000) (3879S, Cell 
Signaling), mouse anti-N-cadherin (1:2500) (05–915, 
Millipore), rabbit anti-SP1 (1:1000) (07–645, Millipore), 
rabbit anti-EGR-1 (1:1000) (sc-110, Santa Cruz 
Biotechnology) or goat anti-actin (1:500) (sc 1616, Santa 
Cruz Biotechnology) were used as primary antibodies. 
The membranes were then washed in TBST and incubated 
for 1 h at room temperature with HRP-coupled goat anti-
rabbit (1:5000) (Santa Cruz Biotechnology) or donkey 
anti-goat (1:5000) (Santa Cruz Biotechnology) secondary 
antibodies. Protein bands were visualized by enhanced 
chemo luminescence (Pierce/Thermo Fisher, Madison, 
WI, USA).
ELISA
hCMEC or GMEC were seeded at 2.6 × 104 cells/
cm2. Indicated treatments were performed in basal 
medium without serum and supplements for indicated time 
periods. Supernatants were harvested and cellular debris 
was removed by centrifugation 1200 rpm for 10 min. 
Supernatants were then concentrated by centrifugation at 
4000 g for 30 min using the Amicon® Ultra 3K device 
3,000 NMWL (Millipore). Protein concentrations in 
supernatants were measured by BCA assay (Pierce 
Biotechnology, Rockford, IL, USA) and equal amounts of 
protein were used for VEGF-A ELISA (BMS277/2TEN, 
eBioscience, Vienna, Austria) and PlGF ELISA 
(RAB0404, Sigma). Pure serum-free medium without 
cells was used as a negative control for all ELISA.
RNA interference
To silence TβRII, ALK-1, ALK-5, endoglin 
or SP1, hCMEC cells were transiently transfected 
using Metafectene Pro transfection reagent (Biontex, 
San Diego, CA, USA) and siRNA pools (100 nM), 
containing four selected siRNA duplexes, each with a 
modification pattern that eliminates off-target effects 
caused by both strands (ON-TARGETplus, SMARTpool, 
(TβRII-L-003930–00, ALK-1- L-005302–02, ALK-5- 
L-003929–00, endoglin-L-011026–00, SP1–026959-00) 
Dharmacon, Lafayette, CO, SA, USA). ON-TARGETplus 
non-targeting pool siRNA (Dharmacon) was used as 
a negative control. For TβRIII, three selected siRNA 
duplexes (S100049595, S100049602, S10049609) were 
used along with a control non-targeting siRNA pool from 
Qiagen (Hilden, Germany) with the same transfection 
reagents and siRNA concentration as used for the silencing 
of other receptors. Gene silencing was verified by qPCR 
and immunoblot as indicated.
Angiogenesis-related in vitro assays
hCMEC were cultured in full medium with TGF-β 
or SD-208 or both for 96 h before being detached using 
accutase (PAA Laboratories, Cölbe, Germany) and 
transferred to growth factor-reduced matrigel (356230, 
BD Biosciences, Franklin Lakes, NJ, USA) in 96 well 
plates at 15,000 cells/50 μl. Tube formation was assessed 
at 4, 12 and 24 h and photographs were taken using a Carl 
Zeiss microscope (Axiovert 100, Göttingen, Germany). 
Tube length (mm), number of tubes (n) and number of 
branching points (n) were calculated as average of 3 
images per condition from independent experiments using 
the Adobe Acrobat X Pro (Adobe, Ireland).
For the sprouting assay, the conditions were same 
as for tube formation except that 2, 000 cells/50 μl were 
transferred to 96 well plates containing growth factor-
reduced matrigel and were left in the matrigel for 7 days. 
Then the number of sprouts formed by the cells was 
counted for 3 images per condition from independent 
experiments using ImageJ 1.40g software (NIH).
Flow cytometry, cell cycle, and viability assays
hCMEC were cultured in full medium followed by 
serum starvation for 24 h in normoxia or hypoxia. The cells 
were then detached using accutase (PAA Laboratories), 
stained with goat anti-VEGFR-1/Flt-1 (AF321, R&D 
Systems), mouse anti-αvβ3 (clone LM609, MAB1976) 
and mouse anti-αvβ5 (clone P1F6, MAB1961) (Merck, 
Darmstadt, Germany) or appropriate isotype controls: 
goat IgG, (sc-2028, Santa Cruz Biotechnology) or mouse 
IgG2a ĸ (550339, BD Biosciences). After 2 washing 
steps with PBS containing 0.5% bovine serum albumin 
(BSA), cells were incubated at 4°C with the following 
secondary antibodies: anti-human alexa fluor 488 
antibody (Invitrogen), anti-goat IgG-FITC (F2016, Sigma 
Aldrich) or anti-mouse IgG1-PE (RMG1–1, Biolegend, 
London, UK). For the detection of endoglin, mouse PE 
anti-human CD105 antibody (323205, Biolegend) or the 
isotype control PE mouse IgG1K (400113, Biolegend) 
and for TβRIII, goat PE anti-human TβRIII (FAB242P, 
R&D Systems) or the isotype control PE goat IgG 
(403004, Biolegend) were used. Subsequently, the cells 
were washed twice with PBS containing 0.5% BSA and 
subjected to flow cytometric analysis. A Cyan® Dako flow 
cytometer was used and data were analyzed via Summit® 
software version 4.3 (Beckmann Coulter, Krefeld, 
Germany). Signal intensity was calculated as the ratio of 
the mean fluorescence of the specific antibody and the 
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isotype control antibody (specific fluorescence index, SFI). 
A SFI of 1.3 was arbitrarily defined as a significant surface 
expression. For some analyses, cells were permeabilized 
by Fix/Perm Buffer Set (Biolegend).
For analysis of cell death, cells were grown in 
6-well plates and treated with TGF-β (10 ng/ml) for 72 h. 
Cells were then harvested, annexin (Anx) V-fluorescein 
isothiocyanate (1:100) and propidium iodide (PI; 50 μg/
ml) were added, and fluorescence in a total of 10,000 
events (cells) per condition was recorded in the flow 
cytometer. Annexin V- or PI-positive cells were counted 
as dead cells, the remaining cells were designated 
the surviving cell fraction. Loss of viability was also 
confirmed by trypan blue dye exclusion [31].
Statistical analysis
Data are commonly derived from experiments 
performed at least twice in duplicates with similar results. 
Quantitative data are represented as mean ± standard 
deviation (SD) from the mean. Statistical significance was 
assessed using the student t-test, one-way ANOVA with 
Tukey’s post hoc test or a two-way ANOVA wherever 
applicable. A p value below 0.05 was considered 
significant. All statistical analyses were performed using 
Prism 5 (GraphPad Software, La Jolla, CA, USA) at p < 
0.05, p < 0.01, p < 0.001 or p < 0.0001.
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